The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen

Vaccine

Volumn 26, Issue 40, 2008, Pages 5145-5152

  Xing, Yiping ^a,b   Huang, Zuhu ^a   Lin, Yan ^a   Li, Jun ^a   Chou, Te Hui ^b   Lu, Shan ^a,b   Wang, Shixia ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DNA vaccine; Glycosylation; Hepatitis B; Surface protein

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; HEPATITIS B S PROTEIN ADR DG23 VACCINE; HEPATITIS B S PROTEIN ADR VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEGLYCOSYLATION; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; WESTERN BLOTTING;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCOSYLATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MICE; MICE, INBRED BALB C; POLYSACCHARIDES; VACCINES, DNA;

EID: 50849100123     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.072     Document Type: Article

References (43)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 24 (1997) 1733-1745
2. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., et al. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 91 6 (1994) 2235-2239
3. Lu X., Mehta A., Dwek R., Butters T., and Block T. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology 213 2 (1995) 660-665
4. Lu X., Mehta A., Dadmarz M., Dwek R., Blumberg B.S., and Block T.M. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc Natl Acad Sci USA 94 6 (1997) 2380-2385
5. Mehta A., Lu X., Block T.M., Blumberg B.S., and Dwek R.A. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci USA 94 5 (1997) 1822-1827
6. Neurath A.R., Seto B., and Strick N. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7 3 (1989) 234-236
7. Gerken G., Kremsdorf D., Capel F., Petit M.A., Dauguet C., Manns M.P., et al. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology 183 2 (1991) 555-565
8. Hui J., Mancini M., Li G., Wang Y., Tiollais P., and Michel M.L. Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor-binding site for hepatocytes. Vaccine 17 13-14 (1999) 1711-1718
9. Petit M.A., Zoulim F., Berthillon P., Capel F., Li J., Dauguet C., et al. PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. J Hepatol 20 1 (1994) 47-56
10. Nakajima E., Minami M., Ochiya T., Kagawa K., and Okanoue T. PreS1 deleted variants of hepatitis B virus in patients with chronic hepatitis. J Hepatol 20 3 (1994) 329-335
11. Coursaget P., Buisson Y., Bourdil C., Yvonnet B., Molinie C., Diop M.T., et al. Antibody response to preS1 in hepatitis-B-virus-induced liver disease and after immunization. Res Virol 141 5 (1990) 563-570
12. Alberti A., Cavalletto D., Pontisso P., Chemello L., Tagariello G., and Belussi F. Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet 1 8600 (1988) 1421-1424
13. Davis H.L., Brazolot Millan C.L., Mancini M., McCluskie M.J., Hadchouel M., Comanita L., et al. DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice. Vaccine 15 8 (1997) 849-852
14. Michel M.L., Davis H.L., Schleef M., Mancini M., Tiollais P., and Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 92 12 (1995) 5307-5311
15. Davis H.L., McCluskie M.J., Gerin J.L., and Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 93 14 (1996) 7213-7218
16. Prange R., and Werr M. DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response. Vaccine 17 7-8 (1999) 617-623
17. Yoon S.J., Park J.W., Ahn S.Y., Choe B.K., and Suh M.H. DNA-mediated immunization of mice with plasmid encoding HBs antigen. J Korean Med Sci 14 2 (1999) 187-192
18. Oka Y., Fazle Akbar S.M., Horiike N., Joko K., and Onji M. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 103 1 (2001) 90-97
19. Davis H.L., Schirmbeck R., Reimann J., and Whalen R.G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 6 11 (1995) 1447-1456
20. Xiao-wen H., Shu-han S., Zhen-lin H., Jun L., Lei J., Feng-juan Z., et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine 23 14 (2005) 1649-1656
21. Rottinghaus S.T., Poland G.A., Jacobson R.M., Barr L.J., and Roy M.J. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21 31 (2003) 4604-4608
22. Wang S., Taaffe J., Parker C., Solórzano A., Cao H., García-Sastre A., et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 80 23 (2006) 11628-11637
23. Wang S., Chou T.H., Sakhatskyy P.V., Huang S., Lawrence J.M., Cao H., et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 79 3 (2005) 1906-1910
24. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90 18 (1993) 8392-8396
25. Chen X., Rock M.T., Hammonds J., Tartaglia J., Shintani A., Currier J., et al. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol 79 9 (2005) 5537-5547
26. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24 21 (2006) 4531-4540
27. Wang S., Heilman D., Liu F., Giehl T., Joshi S., Huang X., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 25-26 (2004) 3348-3357
28. Rock M.T., and Crowe Jr. J.E. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 108 4 (2003) 474-480
29. Ishikawa T., Kono D., Chung J., Fowler P., Theofilopoulos A., Kakumu S., et al. Polyclonality and multispecificity of the CTL response to a single viral epitope. J Immunol 161 11 (1998) 5842-5850
30. Fissolo N., Riedl P., Reimann J., and Schirmbeck R. DNA vaccines prime CD8 + T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequence. Eur J Immunol 35 1 (2005) 117-127
31. Pertmer T.M., Roberts T.R., and Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 70 9 (1996) 6119-6125
32. Feltquate D.M., Heaney S., Webster R.G., and Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158 5 (1997) 2278-2284
33. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 5 5 (1999) 287-300
34. Pancholi P., Lee D.H., Liu Q., Tackney C., Taylor P., Perkus M., et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33 2 (2001) 448-454
35. Shata M.T., Pfahler W., Brotman B., Lee D.H., Tricoche N., Murthy K., et al. Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load. J Med Primatol 35 3 (2006) 165-171
36. Mancini-Bourgine M., Fontaine H., Scott-Algara D., Pol S., Brechot C., and Michel M.L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40 4 (2004) 874-882
37. Mancini-Bourgine M., Fontaine H., Brechot C., Pol S., and Michel M.L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24 21 (2006) 4482-4489
38. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13 1 (2007) 46-53
39. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 7-8 (2000) 764-778
40. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., and Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 22 (1999) 2826-2829
41. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14 2 (1998) 151-155
42. Qiu J.T., Song R., Dettenhofer M., Tian C., August T., Felber B.K., et al. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J Virol 73 11 (1999) 9145-9152
43. Qiu J.T., Liu B., Tian C., Pavlakis G.N., and Yu X.F. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol 74 13 (2000) 5997-6005